title: 3,4,5-Trimethoxycinnamin acid ameliorates restraint stress-induced anxiety and depression.
abstract: The present study investigated whether 3,4,5-trimethoxycinnamic acid (TMCA) treatment ameliorated restraint stress-provoked anxiety- and depression-like behaviors in mice. Fourteen consecutive days of restraint stress produced anxiety- and depression-like behaviors, including reduced time and frequency in the open arms of the elevated plus maze (EPM), as well as enhanced immobility times in the forced swim test (FST). However, TMCA (50 mg/kg) treatment ameliorated this effect; mice showed increased time and frequency of visits in the open arms of the EPM and showed reduced immobility in the FST. In parallel with the behavioral data, long-lasting stimulation of ΔFosB in the nucleus accumbens shell subregion was exhibited in response to TMCA. Furthermore, a reduction in expression of SC1, a target of ΔFosB, in the nucleus accumbens of mice subjected to restraint stress was significantly reversed by TMCA (50 mg/kg) treatment. Collectively, these results suggest that TMCA treatment might provide a therapeutic strategy for treatment of anxiety and depression.
authors.affiliation: Department of Pharmacy, College of Pharmacy, Dankook University, Cheonan-si, Chungnam-do 330-951, Republic of Korea; Department of Molecular Medicine and TIDRC, School of Medicine, Ewha Women's University, Seoul 158-710, Republic of Korea. Electronic address: leemyy@empas.com.
authors.forename: Yea-Hyun
authors.initials: YH
authors.lastname: Leem
authors.affiliation: Department of Molecular Medicine and TIDRC, School of Medicine, Ewha Women's University, Seoul 158-710, Republic of Korea. Electronic address: skoh@ewha.ac.kr.
authors.forename: Seikwan
authors.initials: S
authors.lastname: Oh
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D002934:Cinnamates / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008810:Mice, Inbred C57BL; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D009714:Nucleus Accumbens / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism; D012149:Restraint, Physical; D013315:Stress, Psychological / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D002934:Cinnamates; C483819:Fosb protein, mouse; D009419:Nerve Tissue Proteins; D016760:Proto-Oncogene Proteins c-fos; D012333:RNA, Messenger; D012097:Repressor Proteins; C489290:SC1 protein, mouse; C031619:3,4,5-trimethoxycinnamic acid
keywords: Anxiety; Depression; SC1; TMCA; ΔFosB